Since when did posts mean your opinion is not valid? A lot of posts says got nothing better to do. Real smooth.
Printable View
Since when did posts mean your opinion is not valid? A lot of posts says got nothing better to do. Real smooth.
All cool, people.
We all have to start somewhere.
Just be mindful that number of posts does provide some guidance to other posters - allows them to evaluate the credentials and credibilities of the posters.
There have been a few fly by nighters with backdoor listed stocks (eg. Snake & SeaDragon) who mysteriously disappeared after a few postings.
Gotta be the break through the company was after.........things about to take off for TRUSCREEN??
MKTUPDTE: TRU: TRUSCREEN MAKES STRONG PROGRESS IN FIRST QUARTER FY19 01:02p.m.
TRU
03/07/2018 13:02
MKTUPDTE
PRICE SENSITIVE
REL: 1302 HRS TruScreen Limited
MKTUPDTE: TRU: TRUSCREEN MAKES STRONG PROGRESS IN FIRST QUARTER FY19
3 July 2018
NZX Announcement
TRUSCREEN MAKES STRONG PROGRESS IN FIRST QUARTER FY19
o TruScreen's first quarter sales to 30 June 2018, surpass total sales
in the previous financial year.
o Increased interest and uptake of TruScreen in China:
- A major programme in Xinjiang Province will see TruScreen installed
in 190 hospitals.
- TruScreen chosen as primary screening tool by high tech private
clinic group, with devices to be installed in up to 50 planned women's health
clinics in China.
- The company continues its penetration into hospitals in 16 other
provinces and administrative regions.
Sales for cervical cancer technology company, TruScreen Limited (NZAX:TRU),
have surged in the first quarter of the 2019 financial year and have already
surpassed total sales for FY18.
The majority of these sales are to China, which has seen a significant uplift
in demand following the receipt of CFDA approval for the TruScreen2 device in
December 2017. A significant proportion of these have been sold to
TruScreen's distributors for a major programme in Xinjiang province, which
will see devices installed in 190 hospitals and fully operational over the
next few months.
Programme in Xinjiang Province
TruScreen will be installed in 190 hospitals in the Xinjiang province, over
the coming months. With a population of more than 22 million people, this
initiative in the Xinjiang province will represent penetration into a new
territory for TruScreen.
When fully deployed, each device is expected to utilise up to 150 Single Use
Sensors each month, with a projected annuity income of up to $2.6 million per
year for the company.
Chairman of TruScreen, Robert Hunter, said: "This programme is an indication
of the increasing recognition of our technology in China and the
opportunities now open to us following CFDA approval for our TruScreen2
device. TruScreen successfully completed a rigorous evaluation in Xinjiang,
as part of the approval process, and the programme's commencement will assist
the company to initiate similar programmes in other provinces."
Selection by Chinese Female Health Clinic Group
In addition, TruScreen advises that it has been chosen as the primary
screening solution for a chain of high tech female health clinics to be
established in 50 municipal hospitals in China. Privately owned and operated,
the majority of these new clinics will be located in government women's
hospitals. They are established under the Two Cancers Centre Project and
construction of the first five clinics has already commenced. The clinics aim
to provide a 'one stop screening, diagnosis and treatment centre' for breast
and cervical cancer.
Mr Hunter said: "These clinics will represent the most modern cancer
screening and treatment centres in China, and to be selected as their
cervical cancer screening device places us alongside the most modern and
efficacious technologies available in the world today."
TruScreen has a number of users already in place in China and is focused on
accelerating the sale and installation of its cervical cancer screening
system to both existing and new customers. With the support of its
established and proven distributors, TruScreen is well positioned to
strengthen its existing presence and increase usage of its technology across
the region.
Outlook
As more devices enter the market, TruScreen expects that an increasingly
larger proportion of its revenue from China will be annuity income generated
from the sale of its consumable Single Use Sensors. It estimates that, for
every 100 devices fully deployed in a hospital environment, a sustainable
annuity income stream of approximately $1.4 million will be generated every
year.
The company's new manufacturing facility has now been commissioned and this
increased manufacturing capacity will allow TruScreen to meet the projected
growth in demand for its devices. The company's new facility supplements
existing subcontract manufacturers and will result in increased capacity and
profit margins.
The company anticipates that it will have more than 600 devices deployed in
China by the end of FY19.
ENDS
For more information visit www.truscreen.com or contact:
Martin Dillon
TruScreen Chief Executive Officer
Email: martindillon@truscreen.com
Media Liaison
Jackie Ellis
Email: jackie@ellisandco.co.nz
Phone: +64 27 246 2505
About TruScreen:
TruScreen's real time cervical cancer technology utilises a digital wand
which is placed on the surface of the cervix to measure electrical and
optical signals from the surrounding tissue. A sophisticated proprietary
algorithm framework distinguishes between normal and abnormal (cancerous and
precancerous) tissue to identify precancerous change, or cervical
intraepithelial neoplasia (CIN). A Single Use Sensor (SUS) is used for each
patient to protect against cross-infection.
End CA:00320307 For:TRU Type:MKTUPDTE Time:2018-07-03 13:02:05
Call 0800 ANZ SBT
(0800 269 728)
Email us
Download form
Call 0800 ANZ SBT
(0800 269 728)
Online Multi-Currency A/C
Useful Links
FAQs
Help
©2010 All rights in this site are owned by or licensed to ANZ Bank New Zealand Limited or ANZ New Zealand Securities Limited.
Be scared be very scared !
Its pretty hard to pick holes in that announcement but standby ........................
Good to see some traction/progress although my previous negative comments regarding this company were ultimately in relation to the management as well as those raising capital/pushing the stock. Those facts haven't changed and its therefore a resounding no from me but, again, all the best
.......just the beginning of something big me thinks. Appears to be a very well run, organized and innovative company. Plus an ethical product that is good for womankind worldwide. Maybe Ive got this wrong but I really struggle to find any negatives in the product and clearly they are onto things as far as marketing goes. China's now on board, next stop I believe is India and Mexico.
These "results " are in China , but can they be verified?
Yes, ring the company. Exciting progress at last and more to come.